![]() |
市場調查報告書
商品編碼
1744659
2032 年手術勒除器市場預測:按產品類型、圈套類型、材料、技術、應用、最終用戶和地區進行的全球分析Surgical Snare Market Forecasts to 2032 - Global Analysis By Product Type (Reusable Surgical Snares and Single-use (Disposable) Surgical Snares), Loop Type, Material, Technology, Application, End User and By Geography |
根據 Stratistics MRC 的數據,全球手術勒除器市場預計在 2025 年達到 19 億美元,到 2032 年將達到 28 億美元,預測期內的複合年成長率為 5.8%。
手術勒除器是用於微創手術的專用醫療設備,用於移除、取回和操作體內組織。它們由軟性線圈組成,通常由不銹鋼或合成材料製成。透過手柄操作,它們可以牢固地抓住並切除息肉、病變和其他異常生長物。手術勒除器常用於內視鏡手術,能夠精確、可控制地移除組織,同時最大限度地減少創傷、縮短恢復時間,並提高臨床手術效率。
根據世界衛生組織統計,癌症是全球第一位死因,全球約有1,000萬人死於癌症。其中,最常見的癌症類型是乳癌,約有226萬例;其次是肺癌,約有221萬例;最後是大腸癌,約有193萬例。
慢性病增多
在全球範圍內,大腸直腸癌、發炎性腸道疾病和胃腸道息肉等慢性疾病的負擔日益加重,大大推動了對外科勒除器的需求。由於這些疾病通常需要內視鏡介入診斷和治療,外科勒除器已成為息肉切除和組織取樣的必需工具。慢性疾病的激增也推動了外科勒除器器的普及,並給醫療保健系統施加了採用微創手術的壓力。
先進手術勒除器高成本
手術勒除器的製造和採購成本通常較高,因為它們採用了強化材料、符合人體工學的設計,或具備可旋轉尖端等創新功能。小型診所和醫療機構可能難以投資這些工具,因此可能會選擇較少、成本較低的替代品。此外,報銷挑戰和預算限制也進一步加劇了先進手術設備的採購難度。
拓展尚未開發的新興市場
新興經濟體快速的都市化、醫療基礎設施的改善以及人們對胃腸道健康的日益關注,為市場成長提供了巨大的機會。拉丁美洲、東南亞和中東部分地區等地區的醫療保健投資和內視鏡中心的建立正在增加。隨著這些地區醫療旅遊業的發展,預計對勒除器等微創手術器材的需求將會增加,進一步提升市場滲透率和品牌知名度。
嚴格的報銷政策
保險限制和複雜的核准流程可能會阻礙醫院投資高成本的內視鏡工具。此外,不同地區不同的報銷政策也造成了市場准入的不一致。隨著政府和保險公司越來越重視具有成本效益的治療方法,製造商必須克服監管障礙,以確保其產品得到廣泛應用,從而阻礙市場成長。
新冠疫情擾亂了外科勒除器器市場,影響了供應鏈,並減緩了擇期手術的發展。由於醫院優先考慮急診,內視鏡手術的需求暫時下降。然而,隨著醫療體系的調整,市場逐漸復甦,這得益於對微創手術的日益重視,以減少住院時間和感染風險。疫情也加速了技術進步,促使製造商開發更有效率、更具成本效益的外科勒除器,以滿足不斷變化的醫療保健需求。
可重複使用手術勒除器市場預計將在預測期內成長至最大
可重複使用手術勒除器器預計將在預測期內佔據最大市場佔有率,這得益於其成本效益和在臨床環境中的長期可用性。越來越多的醫療機構採用可重複使用產品,以降低營運成本並減少醫療廢棄物。這些勒除器通常更受醫院的青睞,因為醫院的重複手術使用量較大,重複使用更經濟。
預計預測期內冷勒除器部分將達到最高複合年成長率
預計冷勒除器細分市場將在預測期內實現最高成長率,因為它無需使用電燒即可切除小息肉。對於出血性疾病患者和服用抗凝血劑的患者而言,此方法安全可靠,因為它降低了對周圍組織造成熱損傷的風險。此外,由於操作簡便,可以在門診進行,這也有助於提高冷圈套器的採用率。
在預測期內,亞太地區預計將佔據最大的市場佔有率,這得益於人口快速成長、胃腸道疾病患病率上升以及人們對癌症早期發現意識的不斷提升。中國、印度和日本等國家正在增加對醫療基礎設施的投資,尤其是在內視鏡技術。政府的篩檢計畫和促進早期診斷的舉措也進一步推動了手術勒除器的普及。
預計北美地區在預測期內的複合年成長率最高。這得歸功於內視鏡手術的持續進步和微創技術的廣泛應用。該地區擁有許多優勢,例如成熟的醫療設備產業、健全的報銷制度以及結直腸癌的高發生率,而結直腸癌是勒除器切除術的主要適應症之一。持續的技術創新和主要參與者雄厚的研發資金投入也推動了該地區的快速成長。
According to Stratistics MRC, the Global Surgical Snare Market is accounted for $1.9 billion in 2025 and is expected to reach $2.8 billion by 2032 growing at a CAGR of 5.8% during the forecast period. Surgical snare is a specialized medical device used in minimally invasive procedures to excise, retrieve, or manipulate tissue within the body. It consists of a flexible wire loop, often made of stainless steel or synthetic materials, which are controlled by a handle to securely grasp and cut polyps, lesions, or other abnormal growths. Commonly used in endoscopic surgeries, surgical snares enable precise and controlled removal of tissue while minimizing trauma, reducing recovery time, and enhancing procedural efficiency in clinical settings.
According to WHO, cancer is the leading cause of death, accounting for nearly 10 million deaths worldwide. The most common type of cancer was breast cancer, accounting for nearly 2.26 million cases, followed by lung and colon cancer, accounting for approximately 2.21 and 1.93 million cases, respectively.
Increasing prevalence of chronic diseases
The growing global burden of chronic diseases such as colorectal cancer, inflammatory bowel disease, and gastrointestinal polyps is significantly boosting the demand for surgical snares. As these conditions often require endoscopic interventions for diagnosis and treatment, the use of surgical snares becomes critical for polyp removal and tissue sampling. Thus this surge in chronic illnesses places pressure on healthcare systems to adopt minimally invasive procedures are fueling the adoption of surgical snares.
High cost of advanced surgical snares
Surgical snares incorporate enhanced materials, ergonomic designs, or innovative features like rotatable tips, tend to be expensive to manufacture and procure. Smaller clinics and healthcare facilities may find it difficult to invest in these tools, opting instead for lower-cost alternatives with fewer capabilities. Additionally, reimbursement challenges and budget constraints further complicate the procurement of advanced surgical equipment.
Expansion into untapped emerging markets
Rapid urbanization, improving healthcare infrastructure, and increasing awareness of gastrointestinal health in emerging economies present substantial opportunities for market growth. Regions such as Latin America, Southeast Asia, and parts of the Middle East are experiencing an uptick in healthcare investments and the establishment of endoscopy centers. As medical tourism grows in these areas, demand for minimally invasive surgical tools like snares is expected to rise and facilitate deeper market penetration and brand recognition.
Strict reimbursement policies
Insurance limitations and complex approval processes can deter hospitals from investing in high-cost endoscopic tools. Additionally, variations in reimbursement policies across different regions create inconsistencies in market accessibility. As governments and insurers emphasize cost-effective treatment options, manufacturers must navigate regulatory hurdles to ensure broader adoption of their products hampering the growth of the market.
The COVID-19 pandemic disrupted the surgical snare market, affecting supply chains and delaying elective procedures. Hospitals prioritized emergency treatments, leading to a temporary decline in demand for endoscopic interventions. However, as healthcare systems adapted, the market rebounded with increased focus on minimally invasive surgeries to reduce hospital stays and infection risks. The pandemic also accelerated technological advancements, prompting manufacturers to develop more efficient and cost-effective surgical snares to meet evolving healthcare needs.
The reusable surgical snares segment is expected to be the largest during the forecast period
The reusable surgical snares segment is expected to account for the largest market share during the forecast period due to their cost-efficiency and long-term usability in clinical settings. Healthcare facilities are increasingly adopting reusable options to reduce operational expenses and minimize medical waste. These snares are often preferred in high-volume hospitals where repeated procedures make reuse more economical.
The cold snare segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the cold snare segment is predicted to witness the highest growth rate owing to their advantages in removing small polyps without the use of electrocautery. This method reduces the risk of thermal injury to surrounding tissues, making it safer for patients with bleeding disorders or those on anticoagulants. The simplicity of the technique also makes it accessible for outpatient procedures, contributing to its rising adoption.
During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by a rapidly growing population, increasing prevalence of gastrointestinal diseases, and rising awareness about early cancer detection. Countries such as China, India, and Japan are seeing increased investments in healthcare infrastructure, particularly in endoscopic technology. Government screening programs and initiatives to promote early diagnosis are further driving the adoption of surgical snares.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to ongoing advancements in endoscopic procedures and robust adoption of minimally invasive technologies. The region benefits from a well-established medical device industry, favorable reimbursement systems, and a high prevalence of colorectal cancer, one of the primary indications for snare polypectomy. Continuous innovation by key market players and strong R&D funding also contribute to the rapid growth.
Key players in the market
Some of the key players in Surgical Snare Market include Zimmer Biomet Holdings, Inc., B. Braun Melsungen AG, Smith & Nephew PLC, FUJIFILM Holdings Corporation, Richard Wolf GmbH, Pentax Medical, Karl Storz SE & Co. KG, Stryker Corporation, Veran Medical Technologies (acquired by Boston Scientific), Sklar Surgical Instruments, Medtronic PLC, Olympus Corporation, Steris PLC, Boston Scientific Corporation, Merit Medical Systems, Inc., Avalign Technologies, Inc., Hill-Rom Holdings, CONMED Corporation, and Medline Industries.
In May 2025, Richard Wolf GmbH entered into an agreement with Photocure to develop a high-definition flexible blue light cystoscope for global commercialization.
In May 2025, Merit Medical Systems, Inc. acquired Biolife Delaware, L.L.C., aiming to enhance its product offerings and improve financial performance.
In April 2025, Zimmer Biomet Holdings, Inc. completed the acquisition of Paragon 28 for approximately $1.1 billion, enhancing its portfolio in foot and ankle surgical devices.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.